OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
16 oct. 2018 12h35 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA
11 oct. 2018 09h36 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer
27 sept. 2018 09h51 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Sept. 27, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov
09 juil. 2018 11h31 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., July 09, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
02 juil. 2018 14h37 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., July 02, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
20 juin 2018 08h00 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., June 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
28 mars 2018 09h10 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial
22 mars 2018 09h00 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 22, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
20 mars 2018 09h04 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Appoints Robert Neal Holcomb to Board of Directors
19 mars 2018 09h23 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 19, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...